Inogen Inc (INGN) Expected to Post Quarterly Sales of $61.99 Million

Analysts expect Inogen Inc (NASDAQ:INGN) to report $61.99 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Inogen’s earnings, with the highest sales estimate coming in at $62.20 million and the lowest estimate coming in at $61.67 million. Inogen posted sales of $50.85 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 21.9%. The company is expected to report its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that Inogen will report full year sales of $61.99 million for the current year, with estimates ranging from $242.00 million to $247.80 million. For the next financial year, analysts anticipate that the company will report sales of $297.72 million per share, with estimates ranging from $286.10 million to $304.27 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Inogen.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. Inogen’s revenue for the quarter was up 26.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.25 earnings per share.

A number of brokerages have issued reports on INGN. Zacks Investment Research downgraded Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Leerink Swann reissued an “outperform” rating and set a $120.00 target price (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Finally, Needham & Company LLC increased their target price on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $102.71.

In related news, EVP Matt Scribner sold 2,500 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $112.35, for a total value of $280,875.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Wilkinson sold 30,651 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total value of $3,547,853.25. Following the completion of the sale, the insider now directly owns 38,107 shares of the company’s stock, valued at approximately $4,410,885.25. The disclosure for this sale can be found here. Insiders have sold 113,651 shares of company stock valued at $13,299,463 in the last three months. Insiders own 5.31% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Simplex Trading LLC acquired a new stake in shares of Inogen in the fourth quarter valued at approximately $153,000. Schroder Investment Management Group acquired a new stake in shares of Inogen in the second quarter valued at approximately $132,000. Ameritas Investment Partners Inc. increased its holdings in shares of Inogen by 6.1% in the second quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 86 shares during the last quarter. Pinebridge Investments L.P. increased its holdings in shares of Inogen by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 33 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Inogen in the third quarter valued at approximately $213,000.

Inogen (NASDAQ INGN) opened at $118.12 on Monday. The stock has a market capitalization of $2,465.16, a P/E ratio of 96.03, a price-to-earnings-growth ratio of 4.00 and a beta of 1.13. Inogen has a 1 year low of $62.69 and a 1 year high of $130.05.

TRADEMARK VIOLATION WARNING: “Inogen Inc (INGN) Expected to Post Quarterly Sales of $61.99 Million” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/inogen-inc-ingn-expected-to-post-quarterly-sales-of-61-99-million.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply